{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:29:36Z","timestamp":1792812576731,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Medical Research Council UK (MRC)","award":["MR\/K014854\/1"],"award-info":[{"award-number":["MR\/K014854\/1"]}]},{"DOI":"10.13039\/501100007903","name":"Bloodwise","doi-asserted-by":"publisher","award":["15041"],"award-info":[{"award-number":["15041"]}],"id":[{"id":"10.13039\/501100007903","id-type":"DOI","asserted-by":"publisher"}]},{"name":"KKLF) Clinical training fellowship","award":["KKL838"],"award-info":[{"award-number":["KKL838"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.imlet.2018.01.015","type":"journal-article","created":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T17:25:06Z","timestamp":1517678706000},"page":"74-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["The role of mTOR-mediated signaling in the regulation of cellular migration"],"prefix":"10.1016","volume":"196","author":[{"given":"Ailsa K.","family":"Holroyd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Michie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.imlet.2018.01.015_bib0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell."},{"issue":"27","key":"10.1016\/j.imlet.2018.01.015_bib0010","doi-asserted-by":"crossref","first-page":"20036","DOI":"10.1074\/jbc.M702376200","article-title":"PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding","volume":"282","author":"Wang","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"28","key":"10.1016\/j.imlet.2018.01.015_bib0015","doi-asserted-by":"crossref","first-page":"20329","DOI":"10.1074\/jbc.M702636200","article-title":"The proline-rich Akt substrate of 40\u202fkDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1","volume":"282","author":"Oshiro","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.imlet.2018.01.015_bib0020","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1042\/BJ20070540","article-title":"Identification of Protor as a novel Rictor-binding component of mTOR complex-2","volume":"405","author":"Pearce","year":"2007","journal-title":"Biochem. J."},{"issue":"5022","key":"10.1016\/j.imlet.2018.01.015_bib0025","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1126\/science.1715094","article-title":"Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast","volume":"253","author":"Heitman","year":"1991","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.imlet.2018.01.015_bib0030","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0092-8674(93)90144-F","article-title":"Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression","volume":"73","author":"Kunz","year":"1993","journal-title":"Cell"},{"issue":"39","key":"10.1016\/j.imlet.2018.01.015_bib0035","doi-asserted-by":"crossref","first-page":"41189","DOI":"10.1074\/jbc.M406731200","article-title":"Identification of a PKB\/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase","volume":"279","author":"Feng","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"23","key":"10.1016\/j.imlet.2018.01.015_bib0040","doi-asserted-by":"crossref","first-page":"22473","DOI":"10.1074\/jbc.M500963200","volume":"280","author":"Phillips","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.imlet.2018.01.015_bib0045","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/ncb996","article-title":"Rheb promotes cell growth as a component of the insulin\/TOR signalling network","volume":"5","author":"Saucedo","year":"2003","journal-title":"Nat. Cell Biol."},{"issue":"5712","key":"10.1016\/j.imlet.2018.01.015_bib0050","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.imlet.2018.01.015_bib0055","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cell.2006.08.033","article-title":"SIN1\/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity","volume":"127","author":"Jacinto","year":"2006","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.imlet.2018.01.015_bib0060","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"Sabatini DM: mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"issue":"45","key":"10.1016\/j.imlet.2018.01.015_bib0065","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0809136105","article-title":"Rapamycin differentially inhibits S6 Ks and 4 E-BP1 to mediate cell-type-specific repression of mRNA translation","volume":"105","author":"Choo","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.imlet.2018.01.015_bib0070","doi-asserted-by":"crossref","first-page":"16035","DOI":"10.1038\/nrdp.2016.35","article-title":"Tuberous sclerosis complex","volume":"2","author":"Henske","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"2","key":"10.1016\/j.imlet.2018.01.015_bib0075","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ccr.2008.12.017","article-title":"mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice","volume":"15","author":"Guertin","year":"2009","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.imlet.2018.01.015_bib0080","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/MCB.00601-09","article-title":"mTORC1-activated S6 K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling","volume":"30","author":"Julien","year":"2010","journal-title":"Mol. Cell. Biol."},{"issue":"21","key":"10.1016\/j.imlet.2018.01.015_bib0085","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1128\/MCB.00735-09","article-title":"Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6 K1","volume":"29","author":"Dibble","year":"2009","journal-title":"Mol. Cell. Biol."},{"issue":"37","key":"10.1016\/j.imlet.2018.01.015_bib0090","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1038\/onc.2008.137","article-title":"Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins","volume":"27","author":"Liu","year":"2008","journal-title":"Oncogene"},{"issue":"24","key":"10.1016\/j.imlet.2018.01.015_bib0095","doi-asserted-by":"crossref","first-page":"14253","DOI":"10.1073\/pnas.2332307100","article-title":"Functional identification of distinct sets of antitumor activities mediated by the FKBP gene family","volume":"100","author":"Fong","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.imlet.2018.01.015_bib0100","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1074\/jbc.M116.769216","article-title":"Interaction of p190 A RhoGAP with eIF3 A and Other Translation Preinitiation Factors Suggests a Role in Protein Biosynthesis","volume":"292","author":"Parasuraman","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.imlet.2018.01.015_bib0105","doi-asserted-by":"crossref","first-page":"7136","DOI":"10.18632\/oncotarget.3044","article-title":"Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.imlet.2018.01.015_bib0110","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat. Med."},{"issue":"49","key":"10.1016\/j.imlet.2018.01.015_bib0115","doi-asserted-by":"crossref","first-page":"38362","DOI":"10.1074\/jbc.M110.141168","article-title":"Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity","volume":"285","author":"Liu","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.imlet.2018.01.015_bib0120","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/ncb1183","article-title":"Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive","volume":"6","author":"Jacinto","year":"2004","journal-title":"Nat. Cell Biol."},{"issue":"14","key":"10.1016\/j.imlet.2018.01.015_bib0125","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr. Biol."},{"issue":"7","key":"10.1016\/j.imlet.2018.01.015_bib0130","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1074\/jbc.272.7.3883","article-title":"The Dictyostelium mitogen-activated protein kinase ERK2 is regulated by Ras and cAMP-dependent protein kinase (PKA) and mediates PKA function","volume":"272","author":"Aubry","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.imlet.2018.01.015_bib0135","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1124\/jpet.108.140798","article-title":"A cross-link between protein kinase A and Rho-family GTPases signaling mediates cell\u2013cell adhesion and actin cytoskeleton organization in epithelial cancer cells","volume":"327","author":"Leve","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"10.1016\/j.imlet.2018.01.015_bib0140","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1242\/jcs.177170","article-title":"Protein kinase A regulates the Ras, Rap1 and TORC2 pathways in response to the chemoattractant cAMP in Dictyostelium","volume":"130","author":"Scavello","year":"2017","journal-title":"J. Cell Sci."},{"issue":"21","key":"10.1016\/j.imlet.2018.01.015_bib0145","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1091\/mbc.E13-07-0405","article-title":"Mammalian target of rapamycin and Rictor control neutrophil chemotaxis by regulating Rac\/Cdc42 activity and the actin cytoskeleton","volume":"24","author":"He","year":"2013","journal-title":"Mol. Biol. Cell"},{"issue":"6","key":"10.1016\/j.imlet.2018.01.015_bib0150","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1158\/0008-5472.CAN-07-5869","article-title":"Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival","volume":"68","author":"McDonald","year":"2008","journal-title":"Cancer Res."},{"issue":"23","key":"10.1016\/j.imlet.2018.01.015_bib0155","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1101\/gad.11.23.3218","article-title":"A novel cytosolic regulator, Pianissimo, is required for chemoattractant receptor and G protein-mediated activation of the 12 transmembrane domain adenylyl cyclase in Dictyostelium","volume":"11","author":"Chen","year":"1997","journal-title":"Genes Dev."},{"issue":"22","key":"10.1016\/j.imlet.2018.01.015_bib0160","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0960-9822(07)00511-8","article-title":"The Rho1 effector Pkc1, but not Bni1, mediates signalling from Tor2 to the actin cytoskeleton","volume":"8","author":"Helliwell","year":"1998","journal-title":"Curr. Biol."},{"issue":"6","key":"10.1016\/j.imlet.2018.01.015_bib0165","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.devcel.2010.11.004","article-title":"mTORC2 regulates neutrophil chemotaxis in a cAMP- and RhoA-dependent fashion","volume":"19","author":"Liu","year":"2010","journal-title":"Dev. Cell"},{"issue":"20","key":"10.1016\/j.imlet.2018.01.015_bib0170","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1038\/onc.2012.287","article-title":"Rictor regulates cell migration by suppressing RhoGDI2","volume":"32","author":"Agarwal","year":"2013","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.imlet.2018.01.015_bib0175","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2012-08-452607","article-title":"Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling","volume":"121","author":"Burger","year":"2013","journal-title":"Blood"},{"issue":"5258","key":"10.1016\/j.imlet.2018.01.015_bib0180","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1126\/science.272.5258.60","article-title":"Lymphocyte homing and homeostasis","volume":"272","author":"Butcher","year":"1996","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.imlet.2018.01.015_bib0185","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood.V94.11.3658","article-title":"Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells","volume":"94","author":"Burger","year":"1999","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.imlet.2018.01.015_bib0190","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/blood-2007-05-089409","article-title":"Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia","volume":"110","author":"Burkle","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.imlet.2018.01.015_bib0195","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood.V99.8.2977","article-title":"The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes","volume":"99","author":"Till","year":"2002","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.imlet.2018.01.015_bib0200","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1182\/blood-2014-01-552307","article-title":"Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations","volume":"123","author":"Riches","year":"2014","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.imlet.2018.01.015_bib0205","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1182\/blood-2011-01-333682","article-title":"ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1\/2 activation","volume":"118","author":"Calpe","year":"2011","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.imlet.2018.01.015_bib0210","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1182\/blood-2011-06-275610","article-title":"CD38 and chronic lymphocytic leukemia: a decade later","volume":"118","author":"Malavasi","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.imlet.2018.01.015_bib0215","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/0008-5472.CAN-12-2749","article-title":"CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21-induced motility","volume":"73","author":"Girbl","year":"2013","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.imlet.2018.01.015_bib0220","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1158\/1078-0432.CCR-13-1037","article-title":"CD62 L as a therapeutic target in chronic lymphocytic leukemia","volume":"19","author":"Burgess","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.imlet.2018.01.015_bib0225","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1182\/blood-2006-03-007294","article-title":"MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4 beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration","volume":"108","author":"Redondo-Munoz","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.imlet.2018.01.015_bib0230","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.4049\/jimmunol.1203484","article-title":"Chemokine unresponsiveness of chronic lymphocytic leukemia cells results from impaired endosomal recycling of Rap1 and is associated with a distinctive type of immunological anergy","volume":"191","author":"Pye","year":"2013","journal-title":"J. Immunol."},{"issue":"20","key":"10.1016\/j.imlet.2018.01.015_bib0235","doi-asserted-by":"crossref","first-page":"8429","DOI":"10.1158\/0008-5472.CAN-08-1758","article-title":"Cell motility in chronic lymphocytic leukemia: defective Rap1 and alphaLbeta2 activation by chemokine","volume":"68","author":"Till","year":"2008","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.imlet.2018.01.015_bib0240","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2016-01-683128","article-title":"Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration","volume":"128","author":"Pasikowska","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.imlet.2018.01.015_bib0245","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.imlet.2018.01.015_bib0250","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1182\/blood-2009-05-219634","article-title":"In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia","volume":"114","author":"Calissano","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.imlet.2018.01.015_bib0255","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nri3487","article-title":"New insights into pre-BCR and BCR signalling with relevance to B cell malignancies","volume":"13","author":"Rickert","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"13","key":"10.1016\/j.imlet.2018.01.015_bib0260","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.imlet.2018.01.015_bib0265","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/leu.2012.24","article-title":"Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration","volume":"26","author":"Hoellenriegel","year":"2012","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.imlet.2018.01.015_bib0270","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"de Rooij","year":"2012","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.imlet.2018.01.015_bib0275","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2009-07-233692","article-title":"Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia","volume":"115","author":"Buchner","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.imlet.2018.01.015_bib0280","doi-asserted-by":"crossref","first-page":"e48929","DOI":"10.1371\/journal.pone.0048929","article-title":"Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12","volume":"7","author":"McCaig","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.imlet.2018.01.015_bib0285","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/blood-2005-12-011213","article-title":"Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia","volume":"108","author":"Johnson","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.imlet.2018.01.015_bib0290","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.imlet.2018.01.015_bib0295","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1182\/blood-2010-03-275180","article-title":"The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the E\u03bc- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling","volume":"116","author":"Suljagic","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.imlet.2018.01.015_bib0300","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1182\/blood-2012-09-457119","article-title":"Targeting the LYN\/HS1 signaling axis in chronic lymphocytic leukemia","volume":"121","author":"ten Hacken","year":"2013","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.imlet.2018.01.015_bib0305","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1182\/blood-2011-12-395939","article-title":"RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans","volume":"119","author":"Troeger","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.imlet.2018.01.015_bib0310","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"Vezina","year":"1975","journal-title":"J. Antibiot. (Tokyo)"},{"issue":"1","key":"10.1016\/j.imlet.2018.01.015_bib0315","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1139\/y77-007","article-title":"Inhibition of the immune response by rapamycin, a new antifungal antibiotic","volume":"55","author":"Martel","year":"1977","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"10","key":"10.1016\/j.imlet.2018.01.015_bib0320","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.7164\/antibiotics.37.1231","article-title":"Activity of rapamycin (AY-22,989) against transplanted tumors","volume":"37","author":"Eng","year":"1984","journal-title":"J. Antibiot. (Tokyo)"},{"issue":"22","key":"10.1016\/j.imlet.2018.01.015_bib0325","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.imlet.2018.01.015_bib0330","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.imlet.2018.01.015_bib0335","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00277-008-0582-9","article-title":"A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL","volume":"88","author":"Decker","year":"2009","journal-title":"Ann. Hematol."},{"issue":"9","key":"10.1016\/j.imlet.2018.01.015_bib0340","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/cncr.25005","article-title":"The treatment of recurrent\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation","volume":"116","author":"Zent","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.imlet.2018.01.015_bib0345","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","article-title":"AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity","volume":"70","author":"Chresta","year":"2010","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.imlet.2018.01.015_bib0350","doi-asserted-by":"crossref","first-page":"13962","DOI":"10.18632\/oncotarget.3920","article-title":"AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1\/4 E-BP1 axis","volume":"6","author":"Mi","year":"2015","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.imlet.2018.01.015_bib0355","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.1074\/jbc.M900301200","article-title":"An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1","volume":"284","author":"Thoreen","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.imlet.2018.01.015_bib0360","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/leu.2016.184","article-title":"The pan phosphoinositide 3-kinase\/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib\/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells","volume":"30","author":"Thijssen","year":"2016","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.imlet.2018.01.015_bib0365","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1182\/blood-2014-11-610329","article-title":"The PI3K\/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Emicro-TCL1 mouse model","volume":"125","author":"Blunt","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.imlet.2018.01.015_bib0370","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood-2016-02-700328","article-title":"Dual TORK\/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia","volume":"128","author":"Thijssen","year":"2016","journal-title":"Blood"},{"issue":"7396","key":"10.1016\/j.imlet.2018.01.015_bib0375","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature10912","article-title":"The translational landscape of mTOR signalling steers cancer initiation and metastasis","volume":"485","author":"Hsieh","year":"2012","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.imlet.2018.01.015_bib0380","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/bjc.2016.59","article-title":"A first in man, dose-finding study of the mTORC1\/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies","volume":"114","author":"Mateo","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"19","key":"10.1016\/j.imlet.2018.01.015_bib0385","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1002\/cncr.29422","article-title":"A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1\/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma","volume":"121","author":"Bendell","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.imlet.2018.01.015_bib0390","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1158\/1535-7163.MCT-12-0466","article-title":"VS-5584, a novel and highly selective PI3K\/mTOR kinase inhibitor for the treatment of cancer","volume":"12","author":"Hart","year":"2013","journal-title":"Mol. Cancer. Ther."},{"issue":"1","key":"10.1016\/j.imlet.2018.01.015_bib0395","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/bjh.14181","article-title":"Phase Ib trial of the PI3K\/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies","volume":"175","author":"Awan","year":"2016","journal-title":"Br. J. Haematol."}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247817306065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247817306065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T23:25:27Z","timestamp":1719789927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247817306065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":79,"alternative-id":["S0165247817306065"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2018.01.015","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of mTOR-mediated signaling in the regulation of cellular migration","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2018.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}